Targeting translation dependence in cancer

Oncotarget

Volumn 2, Issue 1-2, 2011, Pages 76-88

  Malina, Abba ^a   Cencic, Regina ^a   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Eif4a; Eif4e; Eif4f; Translation; Translation inhibitor; Translational control

Indexed keywords

4E1RCAT; 4EGI 1; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; INITIATION FACTOR 4F; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEOTIDE DERIVATIVE; PARATHYROID HORMONE; PROTEIN INHIBITOR; RIBAVIRIN; SILVESTROL; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST CANCER; BURKITT LYMPHOMA; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; INITIATION FACTOR 4F GENE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TRANSLATION INITIATION; ANIMAL; DRUG ANTAGONISM; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW;

ANIMALS; EUKARYOTIC INITIATION FACTOR-4F; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 79960856696     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.218     Document Type: Article

References (142)

1. Felsher DW. Reversibility of oncogene-induced cancer. Curr Opin Genet Dev. 2004; 14:37-42.
2. Solimini NL, Luo J Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 2007; 130:986-8.
3. Ingolia NT, Ghaemmaghami S, Newman JR Weissman JS. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science. 2009; 324:218-23.
4. Matthews MB, Sonenberg N Hershey JWB (2007) Origins and Principle of Translation Control. In Translational Control in Biology and Medicine, Matthews MB, Sonenberg N, Hershey JWB, eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), pp. 1-40.
5. Kapp LD Lorsch JR. The molecular mechanics of eukaryotic translation. Annu Rev Biochem. 2004; 73:657-704.
6. Pestova TV, Lorsch JR Hellen CUT (2007) The Mechanism of Translation Initiation in Eukaryotes. In Translational Control in Biology and Medicine, Matthews MB, Sonenberg N, Hershey JWB, eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor) pp. 87-128.
7. Jackson RJ, Hellen CU Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010; 11:113-27.
8. Jang SK, Davies MV, Kaufman RJ Wimmer E. Initiation of protein synthesis by internal entry of ribosomes into the 5' nontranslated region of encephalomyocarditis virus RNA in vivo. J Virol. 1989; 63:1651-60.
9. Gingras AC, Raught B Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem. 1999; 68:913-63.
10. Nielsen PJ Trachsel H. The mouse protein synthesis initiation factor 4A gene family includes two related functional genes which are differentially expressed. EMBO J. 1988; 7:2097-105.
11. Rogers GW, Jr., Komar AA Merrick WC. eIF4A: The godfather of the DEAD box helicases. Prog Nucleic Acid Res Mol Biol. 2002; 72:307-31.
12. Conroy SC, Dever TE, Owens CL Merrick WC. Characterization of the 46,000-dalton subunit of eIF-4F. Arch Biochem Biophys. 1990; 282:363-71.
13. Yoder-Hill J, Pause A, Sonenberg N Merrick WC. The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A. J Biol Chem. 1993; 268:5566-73.
14. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC Schneider RJ. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol. 2008; 181:293-307.
15. Sonenberg N, Morgan MA, Merrick WC Shatkin AJ. A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5'-terminal cap in mRNA. Proc Natl Acad Sci USA. 1978; 75:4843-7.
16. Shatkin AJ, Darzynkiewicz E, Furuichi Y, Kroath H, Morgan MA, Tahara SM Yamakawa M. 5'-Terminal caps, cap-binding proteins and eukaryotic mRNA function. Biochem Soc Symp. 1982; 47:129-43.
17. Marcotrigiano J, Gingras AC, Sonenberg N Burley SK. Cocrystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell. 1997; 89:951-61.
18. Matsuo H, Li H, McGuire AM, Fletcher CM, Gingras AC, Sonenberg N Wagner G. Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein. Nat Struct Biol. 1997; 4:717-24.
19. Pestova TV Kolupaeva VG. The roles of individual eukaryotic translation initiation factors in ribosomal scanning and initiation codon selection. Genes Dev. 2002; 16:2906-22.
20. Yanagiya A, Svitkin YV, Shibata S, Mikami S, Imataka H Sonenberg N. Requirement of RNA binding of mammalian eukaryotic translation initiation factor 4GI (eIF4GI) for efficient interaction of eIF4E with the mRNA cap. Mol Cell Biol. 2009; 29:1661-9.
21. Park EH, Walker SE, Lee JM, Rothenburg S, Lorsch JR Hinnebusch AG. Multiple elements in the eIF4G1 N-terminus promote assembly of eIF4G1*PABP mRNPs in vivo. EMBO J. 2011; 30:302-16.
22. von Der Haar T, Ball PD McCarthy JE. Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5'-Cap by domains of eIF4G. J Biol Chem. 2000; 275:30551-5.
23. Sonenberg N. ATP/Mg++-dependent cross-linking of cap binding proteins to the 5' end of eukaryotic mRNA. Nucleic Acids Res. 1981; 9:1643-56.
24. Rogers GW, Jr., Richter NJ, Lima WF Merrick WC. Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem. 2001; 276:30914-22.
25. Lamphear BJ, Kirchweger R, Skern T Rhoads RE. Mapping of functional domains in eukaryotic protein synthesis initiation factor 4G (eIF4G) with picornaviral proteases. Implications for cap-dependent and cap-independent translational initiation. J Biol Chem. 1995; 270:21975-83.
26. Jacobson A (1996) Poly(A) metabolism and translation: the closed loop model. In In Translational Control in Biology and Medicine, Matthews MB, Sonenberg N, Hershey JWB, eds. (Cold Spring Harbor Press, Cold Spring Harbor), pp. 451-80.
27. Kahvejian A, Svitkin YV, Sukarieh R, M'Boutchou M-N Sonenberg N. Mammalian poly(A)-binding protien is a eukaryotic translation initiation factor, which acts via multiple mechanisms. Genes & Dev. 2005; 19:104-13.
28. Tarun SZ, Jr. Sachs AB. Association of the yeast poly(A) tail binding protein with translation initiation factor eIF-4G. EMBO J. 1996; 15:7168-77.
29. Lazaris-Karatzas A, Montine KS Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature. 1990; 345:544-7.
30. Schneider R Sonenberg N (2007) Translational control in cancer development and progression. In Translational Control in Biology and Medicine, Matthews MB, Sonenberg N Hershey JWB, eds. (Cold SPring Harbor Press, Cold Spring Harbor), pp. 401-31.
31. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004; 428:332-7.
32. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med. 2004; 10:484-6.
33. Petroulakis E, et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell. 2009; 16:439-46.
34. Liang Z, Lei T, LuYing Z YuPing G. The expression of proto-oncogene eIF4E in laryngeal squamous cell carcinoma. Laryngoscope. 2003; 113:1238-43.
35. Kerekatte V, Smiley K, Hu B, Smith A, Gelder F De Benedetti A. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer. 1995; 64:27-31.
36. Li BD, Liu L, Dawson M De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer. 1997; 79:2385-90.
37. Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, Nawas S, McDonald JC DeBenedetti A. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg. 2002; 235:732-8.
38. Nathan CO, Liu L, Li BD, Abreo FW, Nandy I De Benedetti A. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene. 1997; 15:579-84.
39. Sorrells DL, Jr., Ghali GE, De Benedetti A, Nathan CA Li BD. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. J Oral Maxillofac Surg. 1999; 57:294-9.
40. Haydon MS, Googe JD, Sorrells DS, Ghali GE Li BD. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer. 2000; 88:2803-10.
41. Nathan CO, Franklin S, Abreo FW, Nassar R, De Benedetti A Glass J. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol. 1999; 17:2909-14.
42. Franklin S, Pho T, Abreo FW, Nassar R, De Benedetti A, Stucker FJ Nathan CO. Detection of the protooncogene eIF4E in larynx and hypopharynx cancers. Arch Otolaryngol Head Neck Surg. 1999; 125:177-82.
43. Nathan CO, Sanders K, Abreo FW, Nassar R Glass J. Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications. Cancer Res. 2000; 60:3599-604.
44. Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y, Takata I, Segawa Y, Hanafusa T Eguchi K. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res. 2002; 8:3046-53.
45. Wang S, Lloyd RV, Hutzler MJ, Rosenwald IB, Safran MS, Patwardhan NA Khan A. Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma. Thyroid. 2001; 11:1101-7.
46. Rosenwald IB, Hutzler MJ, Wang S, Savas L Fraire AE. Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer. 2001; 92:2164-71.
47. Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L, Chen JJ Woda BA. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am J Pathol. 1999; 155:247-55.
48. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene. 1999; 18:2507-17.
49. Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, Horiuchi S, Shichita M, Yamamoto N Yamamoto M. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res. 2000; 20:2489-94.
50. Martin ME, Perez MI, Redondo C, Alvarez MI, Salinas M Fando JL. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol. 2000; 32:633-42.
51. Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H Igarashi K. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 1997; 57:5041-4.
52. Bauer C, Brass N, Diesinger I, Kayser K, Grasser FA Meese E. Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int J Cancer. 2002; 98:181-5.
53. Bauer C, Diesinger I, Brass N, Steinhart H, Iro H Meese EU. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer. 2001; 92:822-9.
54. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC Schneider RJ. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol. 2009; 11:903-8.
55. Eberle J, Krasagakis K Orfanos CE. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer. 1997; 71:396-401.
56. Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, Horiuchi S, Shichita M, Yamamoto N Yamamoto M. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res. 2000; 20:2489-94.
57. Rosenwald IB. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene. 2004; 23:3230-47.
58. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J Lowe SW. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007; 21:3232-7.
59. Graff JR Zimmer SG. Translational control and metastatic progression: Enhanced activity of the mRNA capbinding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Met. 2003; 20:265-73.
60. Graff JR, Konicek BW, Carter JH Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 2008; 68:631-4.
61. Lawson TG, Ray BK, Dodds JT, Grifo JA, Abramson RD, Merrick WC, Betsch DF, Weith HL Thach RE. Influence of 5' proximal secondary structure on the translational efficiency of eukaryotic mRNAs and on their interaction with initiation factors. J Biol Chem. 1986; 261:13979-89.
62. Pelletier J Sonenberg N. Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell. 1985; 40:515-26.
63. Pelletier J Sonenberg N. Photochemical cross-linking of cap binding proteins to eucaryotic mRNAs: effect of mRNA 5' secondary structure. Mol Cell Biol. 1985; 5:3222-30.
64. Clemens MJ Bommer UA. Translational control: the cancer connection. Int J Biochem Cell Biol. 1999; 31:1-23.
65. Watkins SJ Norbury CJ. Translation initiation and its deregulation during tumorigenesis. Br J Cancer. 2002; 86:1023-7.
66. Hershey JWB Miyamoto S (2000) Translational Control and Cancer. In Translational Control of Gene Expression, Sonenberg, N, Hershey, JWB, Mathews, MB, eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor) pp 637-54.
67. Averous J Proud CG. When translation meets transformation: the mTOR story. Oncogene. 2006; 25:6423-35.
68. De Benedetti A Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004; 23:3189-99.
69. Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK Sonenberg N. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE. 2007; 2:e242.
70. Rajasekhar VK Holland EC. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene. 2004; 23:3248-64.
71. De Benedetti A, Joshi-Barve S, Rinker-Schaeffer C Rhoads RE. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. Mol Cell Biol. 1991; 11:5435-45.
72. Graff JR, Boghaert ER, De Benedetti A, Tudor DL, Zimmer CC, Chan SK Zimmer SG. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer. 1995; 60:255-63.
73. Herbert TP, Fahraeus R, Prescott A, Lane DP Proud CG. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol. 2000; 10:793-6.
74. Zoncu R, Efeyan A Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12:21-35.
75. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC, Jr. Sonenberg N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature. 1994; 371:762-7.
76. Mader S, Lee H, Pause A Sonenberg N. The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol Cell Biol. 1995; 15:4990-7.
77. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G Sonenberg N. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010; 328:1172-6.
78. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006; 314:467-71.
79. Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL, Polakiewicz RD, Sonenberg N Hershey JW. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J. 2004.
80. Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, Matsuhashi S Colburn NH. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A. 1999; 96:14037-42.
81. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N Colburn NH. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 2003; 23:26-37.
82. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M Sonenberg N. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006; 25:2781-91.
83. Duncan R, Milburn SC Hershey JW. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem. 1987; 262:380-8.
84. Tarun SZ, Jr. Sachs AB. A common function for mRNA 5' and 3' ends in translation initiation in yeast. Genes Dev. 1995; 9:2997-3007.
85. Gallie DR. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes & Dev. 1991; 5:2108-16.
86. Preiss T Hentze MW. Dual function of the messenger RNA cap structure in poly(A)-tail-promoted translation in yeast. Nature. 1998; 392:516-20.
87. Iizuka N, Najita L, Franzusoff A Sarnow P. Cap-dependent and cap-independent translation by internal initiation of mRNAs in cell extracts prepared from Saccharomyces cerevisiae. Mol Cell Biol. 1994; 14:7322-30.
88. Michel YM, Poncet D, Piron M, Kean KM Borman AM. Cap-poly(A) synergy in mammalian cell-free extracts. Investigation of the requirements for poly(A)-mediated stimulation of translation initiation. J. Biol. Chem. 2000; 275:32268-76.
89. Svitkin YV, Ovchinnikov LP, Dreyfuss G Sonenberg N. General RNA binding proteins render translation cap dependent. EMBO J. 1996; 15:7147-55.
90. Lang V, Zanchin NI, Lunsdorf H, Tuite M McCarthy JE. Initiation factor eIF-4E of Saccharomyces cerevisiae. Distribution within the cell, binding to mRNA, and consequences of its overproduction. J Biol Chem. 1994; 269:6117-23.
91. Vasilescu S, Ptushkina M, Linz B, Muller PP McCarthy JE. Mutants of eukaryotic initiation factor eIF-4E with altered mRNA cap binding specificity reprogram mRNA selection by ribosomes in Saccharomyces cerevisiae. J Biol Chem. 1996; 271:7030-7.
92. Andreev DE, Dmitriev SE, Terenin IM, Prassolov VS, Merrick WC Shatsky IN. Differential contribution of the m7G-cap to the 5' end-dependent translation initiation of mammalian mRNAs. Nucleic Acids Res. 2009; 37:6135-47.
93. De Gregorio E, Preiss T Hentze MW. Translational activation of uncapped mRNAs by the central part of human eIF4G is 5' end-dependent. RNA. 1998; 4:828-36.
94. De Gregorio E, Preiss T Hentze MW. Translation driven by an eIF4G core domain in vivo. EMBO J. 1999; 18:4865-74.
95. Jefferies HB, Reinhard C, Kozma SC Thomas G. Rapamycin selectively represses translation of the " polypyrimidine tract" mRNA family. Proc Natl Acad Sci U S A. 1994; 91:4441-5.
96. Terada N, Patel HR, Takase K, Kohno K, Nairn AC Gelfand EW. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci U S A. 1994; 91:11477-81.
97. Mendez R, Myers MG, Jr., White MF, Rhoads RE. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol Cell Biol. 1996; 16:2857-64.
98. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, Kogan SC, Nadon R, Housman DE, Lowe SW Pelletier J. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A. 2008; 105:10853-8.
99. Wood LD, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318:1108-13.
100. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001; 98:10314-9.
101. Podsypanina K, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc Natl Acad Sci U S A. 2001; 98:10320-5.
102. Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356:2271-81.
103. Lane HA Breuleux M. Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol. 2009; 21:219-29.
104. Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G Lamb R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol. 2002; 159:217-24.
105. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 2005; 19:1773-8.
106. Shah OJ, Wang Z Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004; 14:1650-6.
107. Thoreen CC Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy. 2009; 5:725-6.
108. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009; 7:e38.
109. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J Lowe SW. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006; 66:7639-46.
110. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2010; 17:249-61.
111. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB Rosen N. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 2010; 18:39-51.
112. Hickey ED, Weber LA, Baglioni C, Kim CH Sarma RH. A relation between inhibition of protein synthesis and conformation of 5'-phosphorylated 7-methylguanosine derivatives. J Mol Biol. 1977; 109:173-83.
113. Cai A, Jankowska-Anyszka M, Centers A, Chlebicka L, Stepinski J, Stolarski R, Darzynkiewicz E Rhoads RE. Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation. Biochemistry. 1999; 38:8538-47.
114. Jemielity J, Kowalska J, Rydzik AM Darzynkiewicz E. Synthetic mRNA cap analogs with a modified triphosphate bridge - synthesis, applications and prospects. New Journal of Chemistry. 2010:829-44.
115. Wagner CR, Iyer VV McIntee EJ. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev. 2000; 20:417-51.
116. Ghosh B, Benyumov AO, Ghosh P, Jia Y, Avdulov S, Dahlberg PS, Peterson M, Smith K, Polunovsky VA, Bitterman PB Wagner CR. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol. 2009; 4:367-77.
117. Kentsis A, Topisirovic I, Culjkovic B, Shao L Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A. 2004; 101:18105-10.
118. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH, Jr. Borden KL. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009; 114:257-60.
119. Tam RC, Lau JY Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother. 2001; 12:261-72.
120. Yan Y, Svitkin Y, Lee JM, Bisaillon M Pelletier J. Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA. 2005; 11:1238-44.
121. Westman B, Beeren L, Grudzien E, Stepinski J, Worch R, Zuberek J, Jemielity J, Stolarski R, Darzynkiewicz E, Rhoads RE Preiss T. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. RNA. 2005; 11:1505-13.
122. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA Wagner G. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 2007; 128:257-67.
123. Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, Qui M, Lewis I, Kurtkaya S, Dingledine R, Fu H, Kozakov D, Vajda S Pelletier J. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A. 2011; 108:1046-51.
124. Rinker-Schaeffer CW, Graff JR, De Benedetti A, Zimmer SG Rhoads RE. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer. 1993; 55:841-7.
125. Graff JR, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 2007; 117:2638-48.
126. Bordeleau ME, Matthews J, Wojnar JM, Lindqvist L, Novac O, Jankowsky E, Sonenberg N, Northcote P, Teesdale-Spittle P Pelletier J. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci U S A. 2005; 102:10460-5.
127. Bordeleau M-E, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, Belsham GJ, Wagner G, Tanaka J Pelletier J. Functional Characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol. 2006; 2:213-20.
128. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco JA, Jr. Pelletier J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest. 2008; 118:2651-60.
129. Bordeleau ME, Cencic R, Lindqvist L, Oberer M, Northcote P, Wagner G Pelletier J. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem Biol. 2006; 13:1287-95.
130. Low WK, Dang Y, Schneider-Poetsch T, Shi Z, Choi NS, Merrick WC, Romo D Liu JO. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell. 2005; 20:709-22.
131. Low WK, Dang Y, Bhat S, Romo D Liu JO. Substrate-Dependent Targeting of Eukaryotic Translation Initiation Factor 4A by Pateamine A: Negation of Domain-Linker Regulation of Activity. Chem Biol. 2007; 14:715-27.
132. Lindqvist L, Oberer M, Reibarkh M, Cencic R, Bordeleau ME, Vogt E, Marintchev A, Tanaka J, Fagotto F, Altmann M, Wagner G Pelletier J. Selective pharmacological targeting of a DEAD box RNA helicase. PLoS ONE. 2008; 3:e1583.
133. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, Porco JA, Jr. Pelletier J. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE. 2009; 4:e5223.
134. Lucas DM, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009.
135. Cencic R, Carrier M, Trnkus A, Porco JA, Jr., Minden M Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res. 2009.
136. Lipton JH, Wetzler M, Nicolini F, Baccarani M, Baer MR, Masszi T, Cram D, Benichou A, Nanda N Cortes JE (2010) Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies. 2010 ASCO Annual Meeting, J Clin Oncol. 2010; abstr 6568.
137. Powell RG, Weisleder D Smith CRJ. Antitumor alkaloids from Cephalotaxus harrintonia: structure and activity. J. Pharm. Sci. 1972; 61:1227-30.
138. Quintas-Cardama A, Kantarjian H Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009; 115:5382-93.
139. Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z, Legrand O Marie JP. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006; 5:723-31.
140. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011; 117:156-64.
141. Robert F, Carrier M, Rawe S, Chen S, Lowe S Pelletier J. Altering chemosensitivity by modulating translation elongation. PLoS ONE. 2009; 4:e5428.
142. Pelletier J Peltz SW (2007) Therapeutic Opportunities in Translation. In Translational Control in Biology and Medicine, Matthews MB, Sonenberg N, Hershey JWB, eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), pp. 855-895.